Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus etomidate for painless gastrointestinal endoscopy in obese adults
ChiCTR2600134925Phase 4Not yet recruiting
- Sponsor
- Yongchuan Hospital Affiliated to Chongqing Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, etomidate and propofol in obesity (3 arms), sponsored by Yongchuan Hospital Affiliated to Chongqing Medical University. Primary endpoints: Respiratory rate, Blood pressure and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
remimazolametomidatepropofol
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2600134925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134925.